X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used to expand and accelerate Ikena’s targeted oncology programs, including both IK-930, a TEAD1 selective Hippo pathway inhibitor, and IK-595, a MEK-RAF complexing inhibitor.
Lead Product(s): IK-930
Therapeutic Area: Oncology Product Name: IK-930
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Ikena Oncology
Deal Size: $43.0 million Upfront Cash: $43.0 million
Deal Type: Financing August 07, 2023
Details:
Through the acquisition, Ikena gains all of Pionyr’s assets including, PY314 and PY159, targeting TREM2 and TREM1 respectively, which are designed to selectively deplete and in some cases reprogram certain tumor-associated macrophages responsible for immunosuppression.
Lead Product(s): PY314,Pembrolizumab
Therapeutic Area: Oncology Product Name: PY314
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Ikena Oncology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition August 07, 2023
Details:
Gilead has waived its exclusive option to acquire Pionyr. Pionyr will be responsible for the development of its pipeline, including PY159, PY314 and PY265. PY159 targeting TREM1 and PY314 targeting TREM2 will continue to advance in Phase 1b studies in multiple solid tumors.
Lead Product(s): PY159,Pembrolizumab
Therapeutic Area: Oncology Product Name: PY159
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition March 23, 2023
Details:
PY265 is a monoclonal antibody targeting macrophage receptor with a collagenous structure (MARCO), a protein expressed on the surfaces of immuno-suppressive myeloid cells including tumor-associated macrophages (TAMs) and monocytic myeloid-derived suppressor cells (MDSCs).
Lead Product(s): PY265,Undisclosed
Therapeutic Area: Oncology Product Name: PY265
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 07, 2022
Details:
First in human clinical experience administering PY159 both alone and in combination with pembrolizumab including identification of target archival tumor specimens from participating patients.
Lead Product(s): PY159,Pembrolizumab
Therapeutic Area: Oncology Product Name: PY159
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 16, 2022
Details:
PY314 was well tolerated over a range of doses both as a single agent and in combination with checkpoint inhibitor pembrolizumab at its label approved dose.
Lead Product(s): PY314,Pembrolizumab
Therapeutic Area: Oncology Product Name: PY314
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
